Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

ABSTRACT:

Purpose

The EMERALD trial led to the approval of elacestrant for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer (mBC) with disease progression following at least one line of endocrine therapy (ET). Subgroup analyses provided evidence suggesting that elacestrant enables ET sequencing in the second line before other targeted combinations, which could delay chemotherapy-based regimens.

Experimental design

This study used claims data from the Komodo Research Dataset linked with Foundation Medicine Inc. clinical genomic data from patients with estrogen receptor+/HER2- mBC harboring an ESR1 mutation treated with elacestrant. The primary outcome measure was time to next treatment (TTNT).

Results

Among 3

SUBMITTER: Rugo HS 

PROVIDER: S-EPMC12770937 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature